When was Gemphire Therapeutics founded?

Gemphire Therapeutics was founded in 2011 and raised its 1st funding round 3 years after it was founded.

Where is Gemphire Therapeutics located?

Gemphire Therapeutics is headquartered in Livonia, United States.

How many employees does Gemphire Therapeutics have?

As of Jun 30, 2026, the latest employee count at Gemphire Therapeutics is 1.

Is Gemphire Therapeutics a funded company?

Gemphire Therapeutics is a funded company, having raised a total of $5M across 4 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Nov 01, 2014.

When was the latest funding round of Gemphire Therapeutics?

Gemphire Therapeutics' latest funding was a $***** Post IPO round on Mar 30, 2017, with participation from 0 investor.

Where does Gemphire Therapeutics rank among its competitors?

Gemphire Therapeutics ranks 60th amongst 184 active competitors, of which 84 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Rejuvenate Bio, which secured $19.5M in Jun, 2026.

Who are the top competitors of Gemphire Therapeutics?

Gemphire Therapeutics' top competitors include Assembly Biosciences, Kailera and Kriya Therapeutics. Among them, Rejuvenate Bio secured the most recent funding round in June, 2026.

Gemphire Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Gemphire Therapeutics is a public company based in Livonia (United States), founded in 2011. It operates as an US-based, clinical-stage biopharma developing small molecule therapeutics for cardio-metabolic diseases. Gemphire Therapeutics has raised $5M in funding. The company has 184 active competitors, including 84 funded and 17 that have exited. Its top competitors include companies like Assembly Biosciences, Kailera and Kriya Therapeutics.

Company Details

Gemphire Therapeutics is a US-based, clinical-stage biopharma developing small molecule therapeutics for cardio-metabolic diseases. Its lead candidate, Gemcabene (CI-1027, dialkyl ether dicarboxylic acid salt) is a small molecule inhibitor of apolipoprotein C-III, formulated as a once-a-day oral drug that targets lipid metabolic pathways to lower LDL-C, hsCRP and triglycerides. Gemcabene's mechanism of action involves blocking of the production of hepatic triglyceride and cholesterol synthesis; and enhancing the clearance of VLDL by decreasing ApoC-III. It is currently in phase 2b trials for Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease and Severe Hypertriglyceridemia.

Website: gemphire.com
Phone Number: +1 **********

Key Metrics

Founded Year

2011

Location

Livonia, United States

Stage

Public

Total Funding

$5M in 4 rounds

Latest Funding Round

Post IPO, Mar 30, 2017, $*****

Investors

Trout Creek Ventures & 7 more

Ranked

60^th among 184 active competitors

Employee Count

1 as on Jun 30, 2026

Similar Companies

Assembly Biosciences & 201 more

Exit Details

Public

View Gemphire Therapeutics' full profile

Gemphire Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neurobo Pharmaceuticals, Inc. CIN: 47-2389984 , United States, Active	Oct 29, 2014	-	5 (As on Mar 31, 2021)	-

Gemphire Therapeutics got listed on Aug 05, 2016.

Click here to take a look at Gemphire Therapeutics's IPO in detail

Gemphire Therapeutics has raised a total funding of $5M over 4 rounds. Its first funding round was on Nov 01, 2014. Gemphire Therapeutics has 8 institutional investors.

Here is the list of recent funding rounds of Gemphire Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 30, 2017	1432548	Post IPO	2103028	3311726	1900925	4147790
Apr 27, 2016	5237926	Conventional Debt	8499497	2022544	6300266	3076628
Apr 02, 2015	2961640	Series A	8091452	9620443	4584592	BlueWater Angels

Access funding benchmarks and valuations. Sign up today!

View details of Gemphire Therapeutics's funding rounds and investors

Gemphire Therapeutics' employee count trend

Gemphire Therapeutics has 1 employees as of Jun 26. Here is Gemphire Therapeutics's employee count trend over the years:

Employee count trend for Gemphire Therapeutics

Uncover Gemphire Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Gemphire Therapeutics include Assembly Biosciences, Kailera and Kriya Therapeutics. Here is the list of Top 10 competitors of Gemphire Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Assembly Biosciences 2005, New York City (United States), Public	Developing novel antivirals to treat serious viral diseases	$700K	Armistice Capital, Avoro Capital & 3 others	67/100
2nd	Kailera 2024, Waltham (United States), Public	Developer of therapies for treating obesity and related conditions	$1B	RTW Investments, Atlas Venture & 12 others	65/100
3rd	Kriya Therapeutics 2012, Redwood City (United States), Series D	Developer of therapeutic solutions for the treatment of diabetes	$938M	Patient Square Capital, Foresite Capital ... & 16 others	64/100
4th	Rejuvenate Bio 2018, San Diego (United States), Series A	Developer of gene therapies for treating chronic and age-related diseases	$34M	VCapital, Digitalis Ventures & 12 others	62/100
5th	Think Bioscience 2019, Boulder (United States), Series A	Provider of synthetic biology platform to develop small-molecule therapeutics	$26M	Innovation Endeavors, Janus Henderson Investors ... & 12 others	62/100
6th	Metsera 2022, New York City (United States), Acquired	Biopharmaceutical company focusing on medicines for obesity and metabolic diseases	$505M	Wellington, Venrock & 15 others	61/100
7th	VTV Therapeutics 1999, High Point (United States), Public	Developer of small molecules for diabetes, muscle weakness and inflammatory diseases	$124M	Samsara BioCapital, Horizon & 12 others	61/100
8th	MicuRx Pharmaceuticals 2007, Foster City (United States), Series E	Develops antibiotics against multidrug-resistant (MDR) superbug infections	$272M	BioVeda China Fund, Legend Capital & 9 others	60/100
9th	Ascletis 2011, Hangzhou (China), Series B	Developer of small molecules for the treatment of multiple diseases	$255M	CBC Group, Goldman Sachs & 5 others	60/100
10th	Marea Therapeutics 2022, San Francisco (United States), Series C	Provider of therapeutics for cardiometabolic diseases	$65.4M	Alpha Wave Global, Third Rock Ventures	59/100
60th	Gemphire Therapeutics 2011, Livonia (United States), Public	US-based, clinical-stage biopharma developing small molecule therapeutics for cardio-metabolic diseases	$5M	Trout Creek Ventures, Excel Venture Management ... & 6 others	39/100